e-learning
resources
Paris 2018
Monday, 17.09.2018
Clinical aspects of pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Epidemiological and Clinical aspects of pulmonary arterial hypertension (PAH)
R. Yahiaoui (Algers, Algeria), Z. Bennoui (Algers, Algeria), D. Hakem (Algers, Algeria), R. Amrane (Algers, Algeria), R. Boughrarou (Algers, Algeria)
Source:
International Congress 2018 – Clinical aspects of pulmonary hypertension
Session:
Clinical aspects of pulmonary hypertension
Session type:
Thematic Poster
Number:
3095
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Yahiaoui (Algers, Algeria), Z. Bennoui (Algers, Algeria), D. Hakem (Algers, Algeria), R. Amrane (Algers, Algeria), R. Boughrarou (Algers, Algeria). Epidemiological and Clinical aspects of pulmonary arterial hypertension (PAH). 3095
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
To code or not to code chronic pulmonary aspergillosis associated malnutrition in PMSI database: that is the problem…
Should we screen for hereditary pulmonary hypertension?
Related content which might interest you:
Macitentan for pulmonary arterial hypertension (PAH): Early clinical experience of 94 patients
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Clinical sildenafil use in Belgian patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Pulmonary circulation II
Year: 2010
Clinical features of pulmonary hypertension
Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2014
Clinical features of pulmonary hypertension
Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2017
Clinical features of pulmonary hypertension
Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease
Year: 2018
Therapeutic potential of DMHCA for pulmonary arterial hypertension (PAH)
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Pregnancy and pulmonary arterial hypertension (PAH)
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II
Year: 2013
Stress-Doppler-Echocardiography for early detection of systemic sclerosis associated pulmonary arterial hypertension
Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases
Year: 2014
An epidemiological study of pulmonary arterial hypertension in Japan
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Risk stratification in pulmonary arterial hypertension (PAH)
Source: International Congress 2018 – New trends in the management of pulmonary hypertension
Year: 2018
Hemodynamic and clinical relevance of “borderline pulmonary hypertension“
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013
Unique characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease compared to the rest of pulmonary arterial hypertension subgroups
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014
Risk assessment in pulmonary arterial hypertension (PAH): Insights from the GRIPHON study
Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension
Year: 2018
Smoking history and pulmonary arterial hypertension (PAH) onset and clinical outcomes (REVEAL)
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Epidemiology of pulmonary hypertension. Preliminary results of the Spanish pulmonary hypertension registry
Source: Annual Congress 2009 - Pulmonary arterial hypertension
Year: 2009
Impact of pulmonary arterial hypertension (PAH) on the lives of patients and carers
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013
Risk assessment in pulmonary arterial hypertension
Source: Eur Respir Rev 2016; 25: 390-398
Year: 2016
Risk assessment in pulmonary arterial hypertension
Source: Eur Respir J, 51 (3) 1800279; 10.1183/13993003.00279-2018
Year: 2018
Risk assessment in pulmonary arterial hypertension
Source: Eur Respir J, 51 (3) 1702606; 10.1183/13993003.02606-2017
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept